ArticleIranian journal of reproductive medicine2013
Comparison of oral dydrogesterone with suppository vaginal progesterone for luteal-phase support in in vitro fertilization (IVF): A randomized clinical trial.
Article in Iranian journal of reproductive medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 4 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- Progestogen therapy in threatened miscarriage and unexplained recurrent pregnancy loss: Recommendations by the Thai interest group.The journal of obstetrics and gynaecology research · 2025Guideline
- Pooled it
- Oral dydrogesterone vs. vaginal progesterone capsules for luteal-phase support in women undergoing embryo transfer: a systematic review and meta-analysis.JBRA assisted reproduction · 2018Pooled it
- Luteal phase support for assisted reproduction cycles.The Cochrane database of systematic reviews · 2015Pooled it
- A randomised control trial on oral dydrogesteroneJournal of medicine and life · 2023Trial
- A Phase III randomized controlled trial comparing the efficacy, safety and tolerability of oral dydrogesterone versus micronized vaginal progesterone for luteal support in in vitro fertilization.Human reproduction (Oxford, England) · 2017Trial
- Article
- Congenital anomalies after first-trimester dydrogesterone therapy during in vitro fertilization.Reproductive biology and endocrinology : RB&E · 2025Article
- First-Trimester Uterine Artery Doppler Indices and Pregnancy Outcomes in Naturally Conceived and Frozen-Thawed Embryo Transfer Cycles.Diagnostics (Basel, Switzerland) · 2025Article
- Comparison of pregnancy outcome after adding oral or intramuscular progesterone to vaginal progesterone in frozen embryo transfer: A cross-sectional study.International journal of reproductive biomedicine · 2024Article
- Comparison of the effect of dydrogesterone and natural micronized progesterone for luteal-phase support in assisted reproductive technology cycles: A single-blind randomized clinical trial study.Health science reports · 2024Article
- Comparison of luteal support protocols in fresh IVF/ICSI cycles: a network meta-analysis.Scientific reports · 2024Article
- Role of Dydrogesterone for Luteal Phase Support in Assisted Reproduction.Reproductive sciences (Thousand Oaks, Calif.) · 2024Review
- The Role of Dydrogesterone in the Management of Luteal Phase Defect: A Comprehensive Review.Cureus · 2023Review
- Association between serum progesterone levels on the day of frozen-thawed embryo transfer and pregnancy outcomes after artificial endometrial preparation.BMC pregnancy and childbirth · 2023Article
- A Comparison of Oral Dydrogesterone with Vaginal Progesterone for Luteal-Phase Support inAdvanced biomedical research · 2023Article
- Secretory products of the corpus luteum and preeclampsia.Human reproduction update · 2021Review
- Endogenous progesterone levels could predict reproductive outcome in frozen embryo replacement cycles supplemented with synthetic progestogens: A retrospective cohort study.Reproductive medicine and biology · 2019Article
- Oral dydrogesterone versus intravaginal micronized progesterone gel for luteal phase support in IVF: a randomized clinical trial.Human reproduction (Oxford, England) · 2018Article
- Live birth rates and safety profile using dydrogesterone for luteal phase support in assisted reproductive techniques.Singapore medical journal · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLuteal phase support is mandatory in assisted reproductive technologies (ART) for optimizing outcome, so the luteal phase is supported with either progesterone, addition of estradiol to progesterone, hCG or gonadotropin releasing hormone (GnRH) agonists. Supplementation of luteal phase with progesterone is prescribed for women undergoing routine IVF treatment.
objectiveTo compare oral dydrogestrone with vaginal progesterone for luteal-phase support in IVF. MATERIALS AND
methodsWe performed this prospective, randomized trial in a tertiary infertility care unit in Taleghani Hospital, Tehran, Iran. In total 80 Women with a history of male factor infertility undergoing controlled ovarian stimulation for IVF treatment (fresh cycle) randomly were divided in two groups (group A or oral dydrogesterone group and group B or vaginal progesterone group). The inclusion criteria were the use of GnRH analogue down-regulation and age less than 40 years old with regular menstrual cycles. All women were euthyroid and normoprolactinemic. Group A (n=40) received 10 mg dydrogesterone QID (40mg daily) and group B (n=40) received 400 mg suppository vaginal progesterone (cyclogest) twice per day (800 mg daily).
resultsClinical pregnancy rate in cyclogest group was higher than dydrogesterone group but the difference was not significant (p=0.52), furthermore the miscarriage rate in two group was the same .The difference between two groups regarding antral follicle, embryo number, luteal-phase duration, endometrial thickness, oocyte number and metaphase-II was not significant (p>0.05).
conclusionThe results showed that oral dydrogesterone is as effective as vaginal progesterone for luteal-phase support in women undergoing IVF.
Indexed as
Identifiers
24639716PMC3941387W48064796What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.